We are delighted to add our latest Educational Series on pomalidomide, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma previously exposed to lenalidomide. This review article includes details on current treatments in relapse/refractory disease and major studies of treatment alternatives.
The review includes guiding commentary from Professor Miles Prince, Professor of Medicine at Melbourne and Monash Universities and Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare.
Please login below to download this issue (PDF)